NCHR’s Testimony to FDA Regarding Reclassification of 4 Medical Devices

September 8, 2020. Thank you for the opportunity to speak today on behalf of the National Center for Health Research. I am Dr. Meg Seymour, a senior fellow at the center. Our center analyzes scientific and medical data to provide objective health information to patients, health professionals, and policy makers. We do not accept funding […]

Read More »

NCHR’s Testimony to FDA on Belantamab Mafodotin

July 14, 2020: Based on the data discussed today, it is difficult to determine how well Belantamab Mafodotin works and whether its effect is clinically meaningful. To approve a treatment for which the benefits do not clearly outweigh the risks creates additional risk for those who are already suffering.

Read More »